photo source: ansa.it

Article published on ansa.it – 23/11/2020

Read the original article on ansa.it

photo source: Il Messaggero

Piero Di Lorenzo is President and CEO of IRBM, the Italian company, located in Pomezia (Rome), currently engaged in the development of the vaccine together with the Jenner Institute of Oxford. The vaccine will then be produced and marketed by AstraZeneca, and Italy has already purchased 70 million doses. Phase III clinical trials will soon be completed, while the results from phase I trials have shown that the “Oxford-IRBM-AstraZeneca” vaccine has an efficacy rate of 90%. It can be stored at a temperature of -4°/-8° C, but Di Lorenzo stresses: «No comparisons with other vaccines: the world and Italy will need several effective products»

Article by Mauro Evangelisti published on Il Messaggero – 12/11/2020

Download pdf

photo source: Fortune Italia

Italian biotech companies often find it difficult to compete internationally. Yet equally often they are recognized as excellence, as in the case of IRBM, which is working on the Covid-19 vaccine R&D. We discussed this with Matteo Liguori, the Managing Director of the company. He points the way to improve the competitiveness of the Italian biotech industry: a system that supports public-private collaboration, investing in innovation, without forgetting that research needs time. Liguori hopes that innovation will be taken into high consideration by the next Financial Act and Recovery Fund. As for the vaccine candidate, he explains the success of the partnership with Oxford and the multinational AstraZeneca: the innovativeness of IRBM is one of its key elements, as well as the previous collaboration with Gsk in the development of the Ebola vaccine. Liguori then answers the questions about the upcoming and hoped-for distribution of the Covid-19 vaccine, and the necessary steps.

Article published on Future Italia – 01/11/2020

Download pdf

photo source: La Stampa

The vaccine candidate developed by the University of Oxford in collaboration with IRBM of Pomezia (Rome), and produced by AstraZeneca, «has triggered a robust immune response in elderly people, the group at highest risk», as revealed by the Financial Times. It’s definitely good news. Piero Di Lorenzo, President of IRBM, announces with optimism that «if phase III of the clinical trial is concluded by December without adverse events, the first 2-3 million doses of the vaccine will arrive in Italy by year end».

Article by Grazia Longo published on La Stampa – 27/10/2020

Download pdf

photo source: ilmessaggero.it

According to the President of IRBM, Di Lorenzo, «if no sudden problem occurs – it is reasonable to believe that the clinical trial phase may be completed by the end of November or in early December». «Once phase 3 is completed – he continued – the possible validation it’s up to the EMA (European Medicines Agency). This process requires up to 12 months in normal times. But these are not normal times», explains Di Lorenzo, stressing that the validation procedure has already started.

Article published on ilmessaggero.it – 21/10/2020

Read the article on ilmessaggero.it

photo source: ansa.it

Article published on ansa.it – 21/10/2020

Read the original article on ansa.it

There are already 10 million doses of the anti-Covid vaccine in Europe. They will reach 20 million within the end of the year, of which 3 million will go to Italy. We are referring to the vaccine developed by the Jenner Institute of the Oxford University, with the collaboration of the Italian company IRBM, based in Pomezia (Rome), and produced with the multinational AstraZeneca. This is the vaccine candidate in which Europe has invested the most. We must wait for the approval of the EMA, which has already started the “rolling review” process. The Italian Minister of Foreign Affairs, Luigi Di Maio: «The first doses of the vaccine will arrive by the end of the year. Vaccinations will begin in early 2021»

Article by Mauro Evangelisti published on Il Messaggero – 12/10/2020

Download pdf

photo source: La Stampa

After the announcement made by the EMA, the finishing line of getting a coronavirus vaccine is now closer for IRBM, the Italian company based in Pomezia (Rome). The vaccine candidate developed in collaboration with the University of Oxford and produced by the multinational AstraZeneca «is the first in western world to be considered by a regulatory agency» says the President of IRBM, Piero Di Lorenzo. The goal is close but in the meantime «you should get vaccinated against influenza to train your immune system» recommends Di Lorenzo.

Article by Maria Rosa Tomasello published on La Stampa – 02/10/2020

Download pdf

photo source: Il Riformista

Stock market could be in the future of IRBM, the Italian company that collaborates in the vaccine development with the Jenner Institute of Oxford and the British pharmaceutical company AstraZeneca. The President of IRBM, Piero Di Lorenzo, admits: «We receive many partnership proposals, several big companies would like to buy the shares. Many people are interested in us all over the world, I don’t rule out any option». But there is no time to consider this opportunity until the vaccine is validated. Di Lorenzo talks about the clinical trials currently ongoing, pointing out that while technical times have been shortened, those of experimentation continue to be respected.

Article by Riccardo Amati published on Il Riformista – 28/09/2020

Download pdf

The EU Commission has signed an agreement for the purchase of 300 million doses of the vaccine produced by the Jenner Institute of Oxford University and the company Advent based in Pomezia (Rome). Under the deal with AstraZeneca, the doses will be distributed to all Member States. Stella Kyriakides, Commissioner for Health and Food Safety, stressed the commitment made by France, Germany, Italy and the Netherlands.

Article published on Latina Oggi – 28/08/2020

Download pdf